{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:38:54Z","timestamp":1790163534290,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":3693,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1038\/modpathol.2012.141","type":"journal-article","created":{"date-parts":[[2012,8,17]],"date-time":"2012-08-17T07:47:13Z","timestamp":1345189633000},"page":"1623-1628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Activity and complexes of mTOR in diffuse large B-cell lymphomas\u2014a tissue microarray study"],"prefix":"10.1016","volume":"25","author":[{"given":"Anna","family":"Sebesty\u00e9n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s B","family":"Sticz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gnes","family":"M\u00e1rk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Hajdu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Botond","family":"Tim\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Nemes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mi","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zs\u00f3fia","family":"V\u00e1radi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Kopper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/modpathol.2012.141_bib1","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2012.141_bib2","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s00277-010-0990-5","article-title":"A systematic review and meta-analysis of rituximab-based immunochemotherapy for subtypes of diffuse large B cell lymphoma","volume":"89","author":"Fang","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1038\/modpathol.2012.141_bib3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1053\/j.seminhematol.2008.02.003","article-title":"Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphoma","volume":"45","author":"Kahl","year":"2008","journal-title":"Semin Hematol"},{"key":"10.1038\/modpathol.2012.141_bib4","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1182\/blood-2010-12-322362","article-title":"Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"117","author":"Gutierrez-Garcia","year":"2011","journal-title":"Blood"},{"key":"10.1038\/modpathol.2012.141_bib5","doi-asserted-by":"crossref","first-page":"530","DOI":"10.18632\/oncotarget.188","article-title":"Targeting the PI3K\/Akt\/mTOR pathway\u2013beyond rapalogs","volume":"1","author":"Markman","year":"2010","journal-title":"Oncotarget"},{"key":"10.1038\/modpathol.2012.141_bib6","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1186\/1471-2407-11-505","article-title":"Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer","volume":"11","author":"Huijts","year":"2011","journal-title":"BMC cancer"},{"key":"10.1038\/modpathol.2012.141_bib7","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/modpathol.3800525","article-title":"The Akt pathway in human breast cancer: a tissue-array-based analysis","volume":"19","author":"Bose","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1038\/modpathol.2012.141_bib8","first-page":"339","article-title":"mTOR as a target for cancer therapy","volume":"279","author":"Houghton","year":"2004","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1038\/modpathol.2012.141_bib9","doi-asserted-by":"crossref","first-page":"14071","DOI":"10.1074\/jbc.R109.094003","article-title":"Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony","volume":"285","author":"Foster","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1038\/modpathol.2012.141_bib10","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1172\/JCI44145","article-title":"Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy","volume":"121","author":"Wander","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1038\/modpathol.2012.141_bib11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00726-008-0230-7","article-title":"mTOR phosphorylated at S2448 binds to raptor and rictor","volume":"38","author":"Rosner","year":"2010","journal-title":"Amino Acids"},{"key":"10.1038\/modpathol.2012.141_bib12","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.molmed.2007.04.002","article-title":"mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer","volume":"13","author":"Dann","year":"2007","journal-title":"Trends Mol Med"},{"key":"10.1038\/modpathol.2012.141_bib13","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.bbrc.2007.07.151","article-title":"Rapamycin regulates the phosphorylation of rictor","volume":"362","author":"Akcakanat","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1038\/modpathol.2012.141_bib14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol Cell"},{"key":"10.1038\/modpathol.2012.141_bib15","first-page":"55","article-title":"Tissue-microarray based immunohistochemical analysis of survival pathways in nodular sclerosing classical Hodgkin lymphoma as compared with Non-Hodgkin's lymphoma","volume":"3","author":"De","year":"2010","journal-title":"Int J Clin Exp Med"},{"key":"10.1038\/modpathol.2012.141_bib16","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1200\/JCO.2010.29.2813","article-title":"Temsirolimus Has Activity in Non-Mantle Cell Non-Hodgkin's Lymphoma Subtypes: the University of Chicago Phase II Consortium","volume":"28","author":"Smith","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2012.141_bib17","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/asheducation-2010.1.265","article-title":"Signal transduction inhibitor therapy for lymphoma","volume":"2010","author":"Witzig","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1038\/modpathol.2012.141_bib18","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/leu.2010.226","article-title":"A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma","volume":"25","author":"Witzig","year":"2011","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2012.141_bib19","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JCO.2010.30.0368","article-title":"Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"29","author":"Meyer","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2012.141_bib20","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1053\/j.seminhematol.2011.05.001","article-title":"Molecular targeted approaches in mantle cell lymphoma","volume":"48","author":"Weniger","year":"2011","journal-title":"Semin Hematol"},{"key":"10.1038\/modpathol.2012.141_bib21","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1158\/1078-0432.CCR-08-1543","article-title":"Phospho-p70S6K\/p85S6K and cdc2\/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy","volume":"15","author":"Zhao","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1038\/modpathol.2012.141_bib22","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/path.2807","article-title":"The molecular background of aggressive B cell lymphomas as a basis for targeted therapy","volume":"223","author":"de Jong","year":"2011","journal-title":"J Pathol"},{"key":"10.1038\/modpathol.2012.141_bib23","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1128\/MCB.00601-09","article-title":"mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling","volume":"30","author":"Julien","year":"2010","journal-title":"Mol Cell Biol"},{"key":"10.1038\/modpathol.2012.141_bib24","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/path.2747","article-title":"Prognostic significance of XIAP expression in DLBCL and effect of its inhibition on AKT signalling","volume":"222","author":"Hussain","year":"2010","journal-title":"J Pathol"},{"key":"10.1038\/modpathol.2012.141_bib25","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1365-2141.2010.08123.x","article-title":"High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"149","author":"Hasselblom","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1038\/modpathol.2012.141_bib26","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1182\/blood-2010-06-255067","article-title":"Novel therapeutic agents for B-cell lymphoma: developing rational combinations","volume":"117","author":"Reeder","year":"2011","journal-title":"Blood"},{"key":"10.1038\/modpathol.2012.141_bib27","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nrd3531","article-title":"Rapamycin passes the torch: a new generation of mTOR inhibitors","volume":"10","author":"Benjamin","year":"2011","journal-title":"Nat Rev Drug Discov"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/modpathol2012141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol2012141","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222029507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222029507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol2012141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:05:23Z","timestamp":1760231123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222029507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0893395222029507"],"URL":"https:\/\/doi.org\/10.1038\/modpathol.2012.141","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity and complexes of mTOR in diffuse large B-cell lymphomas\u2014a tissue microarray study","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/modpathol.2012.141","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2012 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}